Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

BACKGROUND: Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogino, Hirokazu, Taylor, Jennie W., Nejo, Takahide, Gibson, David, Watchmaker, Payal B., Okada, Kaori, Saijo, Atsuro, Tedesco, Meghan R., Shai, Anny, Wong, Cynthia M., Rabbitt, Jane E., Olin, Michael R., Moertel, Christopher L., Nishioka, Yasuhiko, Salazar, Andres M., Molinaro, Annette M., Phillips, Joanna J., Butowski, Nicholas A., Clarke, Jennifer L., Oberheim Bush, Nancy Ann, Hervey-Jumper, Shawn L., Theodosopoulos, Philip, Chang, Susan M., Berger, Mitchel S., Okada, Hideho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803342/
https://www.ncbi.nlm.nih.gov/pubmed/34882581
http://dx.doi.org/10.1172/JCI151239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803342/
https://www.ncbi.nlm.nih.gov/pubmed/34882581
http://dx.doi.org/10.1172/JCI151239

Ejemplares similares